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Abstract: Several studies have shown that gastrocnemius is frequently injured in triathletes. The
causes of these injuries are similar to those that cause the appearance of the myofascial pain syndrome
(MPS). The ischemic compression technique (ICT) and deep dry needling (DDN) are considered
two of the main MPS treatment methods in latent myofascial trigger points (MTrPs). In this study
superficial electromyographic (EMG) activity in lateral and medial gastrocnemius of triathletes with
latent MTrPs was measured before and immediately after either DDN or ICT treatment. Taking into
account superficial EMG activity of lateral and medial gastrocnemius, the immediate effectiveness
in latent MTrPs of both DDN and ICT was compared. A total of 34 triathletes was randomly
divided in two groups. The first and second groups (n = 17 in each group) underwent only one
session of DDN and ICT, respectively. EMG measurement of gastrocnemius was assessed before
and immediately after treatment. Statistically significant differences (p = 0.037) were shown for a
reduction of superficial EMG measurements differences (%) of the experimental group (DDN) with
respect to the intervention group (ICT) at a speed of 1 m/s immediately after both interventions,
although not at speeds of 1.5 m/s or 2.5 m/s. A statistically significant linear regression prediction
model was shown for EMG outcome measurement differences at V1 (speed of 1 m/s) which was only
predicted for the treatment group (R2 = 0.129; β = 8.054; F = 4.734; p = 0.037) showing a reduction
of this difference under DDN treatment. DDN administration requires experience and excellent
anatomical knowledge. According to our findings immediately after treatment of latent MTrPs, DDN
could be advisable for triathletes who train at a speed lower than 1 m/s, while ICT could be a more
advisable technique than DDN for training or competitions at speeds greater than 1.5 m/s.
Keywords: myofascial pain syndrome; trigger points; electromyography; deep dry needling; is-
chemic pressure technique
1. Introduction
The triceps surae complex includes both gastrocnemius and soleus muscles with
attachments proximally at the posterior part of the knee and distally at the posterior part
of the ankle [1], respectively. The triceps surae assists in control of the knee and ankle and
thus, plays a role in all lower extremity activities including triathlon [2,3]. Currently, a
triathlon (swimming, cycling, running) is a growing sport activity [4], with an exponential
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increase in their annual licenses [5]. Several studies have shown that the area that suffers
the greatest number of injuries in this sport is the triceps surae [6,7].
Myofascial pain syndrome (MPS) is a regional pain condition associated with the
presence of myofascial trigger points (MTrPs) [8]. The presence of MTrPs is considered
to be the first sign of muscle overload [9]. This disorder can affect any skeletal muscle
in the body and it usually accounts for 21% of orthopaedic clinic visits, 30% of general
medicine visits, and around 85%–93% of patients who are referred to pain management
clinics [10]. MPS usually occurs in unconditioned muscles, under high tension conditions
or after direct local trauma or strains [11]. The presence of MTrPs is linked to overuse and
inappropriate muscle use [8].
MTrPs which may be considered as the primary source of pain in MPS were defined
as hyperirritable spots within a taut band of skeletal muscle [12]. Two different kinds of
MTrPs were divided according to their classification by clinical activity: (1) latent and
(2) active MTrPs [9,13]. Latent MTrPs can develop after maintaining muscle activation for
long periods of time, exaggerated muscle contractions, or repeated physical activity. Latent
MTrPs pain can be triggered by digital compression, stretching, and/or overload [10].
A very high percentage of injuries in triathlon usually occur mainly for two reasons:
(1) micro-trauma of repetition or traumatisms and (2) muscular overuse [14], both of which
are the main reason for the appearance of MPS [15].
Treatment of this musculoskeletal condition includes deactivation of MTrPs by pro-
cedures such as deep dry needling (DDN) or ischemic compression technique (ICT), in
order to evaluate their effects on pain and functionality. DDN is considered as a safe and
effective method for decreasing pain and improving function by eliciting a local twitch
response (LTR) in the MTrPs [16]. Active MTrPs are associated with higher motor end plate
noise than latent MTrPs, which means that latent MTrPs can display less irritability than
active MTrPs and local twitch responses could be elicited with more difficulty [17]. Eliciting
LTR during treatment with DDN would modulate a motor-neuron activity and disrupt
the abnormal motor end plante activity [18]. The evidence suggests that this method of
treatment performed by physical therapists was more effective than no treatment, sham
dry needling and/or other types of treatment [19].
Another efficient technique for treating MTrPs is manual local ICT [20], whereby a
pressure for 90 s using the thumb is applied to the MTrP [21]. ICT is considered the most
common, non-invasive therapy currently used for the treatment of MTrPs [22].
Diverse studies report alterations in muscle function such as, electromyographic activ-
ity increased in the antagonist and synergists muscles of subjects with latent MTrPs [23,24],
muscle fatigue increased and overload of motor units close to the latent MTrPs [25]. More-
over, latent MTrPs contribute to accelerated fatigability [26].
When performing a surface electromyography (EMG) of the muscles with MTrPs,
resting activity is rarely recorded in them, but they usually show increased motor activity
during contraction [10]; however, when the test is performed by means of an intramuscular
needle EMG; of an unstimulated MTrP, greater spontaneous activity is observed in MTrP
locations than in sites located outside of these MTrPs [27,28]. Spontaneous electrical activity
(SEA) is an indication of spontaneous release of acetylcholine (ACh) at the neuromuscular
junction (NMJ) [29]. This activity is characteristic of both active and latent MTrPs, which is
recorded with an EMG intramuscular needle, when the muscle is at rest. The potential of
the terminal motor plate in dysfunction of the extrafusal fibre of the muscle, may present
two characteristics under the presence of an MTrP: (1) On one hand, a low degree of
continuous electrical activity is present and represents an abnormal activity of end plate or
end plate noise and (2) on the other hand, higher amplitude peaks or end plate peaks are
accompanied by end plate noise of latent MTrPs [28].
Stimulation of a latent MTrPs (either by ICT or DDN) induces local pain and/or
referred pain and presents a lower degree of pain in latent MTrPs than in active ones,
without finding any type of end plate noise in areas of non-MTrPs [27].
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The mode of action of the DDN is associated withs both mechanical and neurophysio-
logical mechanisms, but still the specific mechanism of action of the DDN is not yet known
exactly [30,31]. It is intended that the mechanical effects of the needle interrupt the integrity
of the terminal motor plate in dysfunction [32] and alterations in the length and tension
of muscle fibres [33] increase blood flow in the muscle and therefore oxygenation there
in [33,34]. Kubo et al. found that DDN caused an increase in blood flow at the needling
site, for 30 min starting at the moment of needling onwards [33]. Sato et al. described that
the release of vasoactive substance, such as calcitonin gene-related peptide (CGRP) and
substance p (SP) leads to vasodilatation in small vessels and increased blood flow [35].
Until now we have not found any article that measures the muscle activity in the
gastrocnemius at an electromyographic level immediately after the latent PGM puncture is
carried out, for this reason we have considered it relevant to carry out this investigation, in
order to demonstrate whether the proven acceleration of muscle fatigue typical of latent
PGM is reduced immediately after treatment with PSP and/or ICT, as measured by surface
electromyography.
The aim of the study was to compare the immediate effectiveness in latent medial
and lateral gastrocnemius MTrPs of both DDN and ICT assessed by superficial EMG. We
hypothesized a greater improvement in EMG activity in triathletes who received DDN
than in those receiving ICT.
2. Methods
2.1. Design
The current study was a secondary analysis of a single blinded clinical trial [36]
that used a randomized between-group design to investigate the immediate superficial
electromiographic effects of DDN treatment with a single session of this technique versus
a single treatment session of ICT. Both treatments were applied to latent medial and
lateral gastrocnemius MTrPs of medium-distance triathletes. The principal outcome of
this clincal trial was identification of EMG activity over the latent treated MTrPs. This
superficial EMG measurement was carried out for both groups of triathletes according
to our previously published randomized clinical trial protocol [36]. Measurements were
made in all participants by a blinded evaluator before and 5, 10, 15, 20 and 25 min after
treatment session and those measurements were made 24 h after the last sport session. The
study was approved by the human research committee of the Hospital Clinico San Carlos,
Madrid-Spain (CEIC Hospital Clínico San Carlos 02/17), and before participation in the
study all subjects signed an informed consent form. This clinical trial was prospectively
registered at Clinicaltrials.gov with the number NCT03273985.
2.2. Participants
Participants in this study were medium distance triathletes ((1.9 km of swimming,
90 km of cycling, and 21 km of running) [4] who were recruited from the podiatric and
physiotherapy clinic, Fisiofuenla s.l.p, from September to December 2017, according to a
randomized sampling method. All of them had ≥3 years of experience participating in
triathlons and they trained around 15 to 20 h weekly. They were selected after identifying
them via a clinical exploration conducted by the principal investigator in which, the pres-
ence in gastrocnemius of latent MTrPs in the places determined by Travell and Simons [37]
as the most common and symptomatic, and identification based on selection criteria were
used to select the participants. All participants were evaluated by the same principal
investigator who has extensive experience, at least three years, in MTrPs diagnosis and its
treatment, which increased confidence in the identification of MTrPs [38]. Inclusion criteria
necessary for the participation of triathletes in the study consisted of two parameters:
(1) presence of a knot or hypersensitive point in the taut band of skeletal muscle and
(2) presence of local or referred pain after mechanical stimulation in the superficial area of
the latent MTrP. Several criteria were used to exclude the triathlete from the study: (1) Age
> 75 and <18 years; (2) score ≥ 4 on the Douler Neuropathique 4 (DN4) questionnaire,
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which denotes lower limb neurological disorders [39]; (3) cognitive alterations according
to positive results on the Pfeiffer questionnaire [40]; (4) taking anticoagulant or antiaggre-
gant medication; (5) existence of prosthesis in the lower limb; (6) presence of systemic or
local infection in the lower limb; (7) fibromyalgia, autoimmune disease, iron deficiency, or
hypothyroidism; and (8) fear of needles.
2.3. Simple Size Calculation
A sample size calculation using the G*Power 3.1.9.2 software (G*Power©; University
of Dusseldorf, Dusseldorf, Germany) was obtained according to the difference between
two independent groups. This calculation was based on the EMG percentage (%) at a
medium speed of 1.5 m/s (V2) for voluntary isometric maximum force contraction (MVC)
of the latent MTrP of medial and lateral gastrocnemius muscle measured immediately after
interventions. A pilot study (n = 12) with two groups consisting of six triathletes in the
experimental group who received DDN (expressed as mean ± standard deviation [SD] of
22.96% ± 8.38%) and six triathletes in the intervention group who received ICT (35.41%
± 16.24%) [41] was initially conducted. In addition, a one-tailed hypothesis, effect size of
0.96, α error probability of 0.05, power (1-β error probability) of 0.80, and allocation ratio
N2/N1 = 1 were used in order to determine the suitable sample size calculation. Therefore,
a sample size of 30 triathletes was calculated with an actual power of 0.82. Finally, regarding
possible 10% loss during follow-up, a total sample size of 34 triathletes with ± 17 triathletes
in each of the experimental groups (DDN and ICT, respectively), was used.
2.4. Principal Outcome: Electromyographic Measurement
A double channel surface bipolar EMG was used to measure muscular activity in
the gastrocnemius, (Verity Medical Ltd., Hans, UK), EMG ranged from 0.2 to 2000 µV
root mean square (RMS prolonged) with a sensitivity of 0.1 µV RMS, accuracy of 4% of
indications µV 0.3 µV at 200 Hz, and selective band filter of bandwidth 3 dB differential
instrumentation amplifier.
Electrode preparation and placement of was carried out following the Surface EMG
Recommendations for Non-invasive Assessment of Muscles (SENIAM) recommenda-
tions [42]. The two electrodes were placed longitudinally after careful preparation of the
skin in which each muscle was cleaned with 70% alcohol, marked with and indelible
marker and then shaved. The skin was shaved and scratched with fine sandpaper and
then cleaned with ethyl alcohol [43]. The electrodes were secured with hypoallergenic
adhesive plaster [42] and an elastic bandage was placed on them [44] in order to prevent
their movement.
The location of surface electrodes was established by SENIAM protocol. According
to the protocol, the first electrode should be located in external gastrocnemius near the
junction line between the fibula head and heel. We placed the electrode at 1/3 of the
fibula head following the line of junction [45]. The second one was located in internal
gastrocnemius the electrodes were placed on the most promising area of the muscle [45].
Silver or silver/chloride electrodes with rectangular shape and a measure of 4× 5 mm
embedded in a round gel pad of 10 mm diameter (MedicotestGmbH, Andernach, Germany)
were used and the reference ground electrode was placed in a free area of the muscle over
the femur [42].
This study was divided into two parts. First, the patient was asked for a voluntary
isometric maximum force contraction (MVC) [46] after receiving precise instructions on
how to perform the MVC of the muscle in question. Three maximal attempts of 6 s each
were performed, separated by 3 min to recover from medial and lateral gastrocnemius
fatigue, and only the best performance was chosen for the statistical analysis [47]. The
participants were instructed to exert maximum effort against resistance. Patients were
placed in prone position, and a plantar flexion movement of the tibio-fibular talar joint,
with the knee extended (a specialized therapist exerted maximum resistance on the sole
of the foot) [48] was required. Patients were verbally encouraged while performing the
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evaluation. The purpose of this test is to allow the researcher to compare the maximum
amplitudes with submaximal tasks, such as walking [44].
Certain studies with intramuscular EMG indicate that muscle with latent MTrP fa-
tigues faster than normal muscles [26]. In 2011 Hong and Arendt Nielsen showed that
reduction in mean power spectral frequency of intramuscular EMG activity occurred earlier
in latent MTrPs than in normal muscle fibers [26].
Therefore, according to the SENIAM protocol, a comparison was carried out with
EMG measurement on the same reference points in the affected leg [42], before and after
treatment. The measurements were taken in order to evaluate muscle activity in the
gastrocnemius with the superficial EMG selected for this study showing high intra and
inter-examiner reliabilities (intraclass correlation coefficient from [ICC] ranging from 0.94
to 0.98). This measurement was performed in the second part of the test protocol at three
different speeds on a treadmill before and after treatment (V1: 1 m/sg, V2: 1.5 m/sg, and
V3: 2.5 m/sg). To determine the fastest speed that the subject could successfully complete,
they were urged to begin the test on the treadmill for the lowest speed before and after
treatment. If the patient could walk comfortably at this speed during the assigned 2 min
period, the speed of the treadmill was increased to the next level. The study continued
until maximum speed data were collected on the treadmill or until the subject could not
maintain the established speed [48].
To carry out the data analysis (Software Watscope, Digital North Inc. Waterloo, ON,
Canada), the first and last 5 s of the EMG study signals were selected, and the mean power
frequency (FPM) was calculated in each segment [49].
2.5. Treatment Allocation
First, an external researcher collected the necessary subject data who participated
in this study. Afterwards, the distribution of the same was carried out in both groups,
DDN or ICT. This distribution was determined with the statistical and epidemiological
analysis system called Epidat 4.2 (Consejería de Sanidad, Xunta de Galicia (España);
Organización Panamericana de Salud (OPS-OMS); Universidad CES Colombia). Individual
and numbered sheets were prepared sequentially with randomized assignment and placed
in sealed opaque envelopes. A second investigator was in charge of opening the envelope.
Each variable was measured five times before and after the intervention by an independent
investigator.
2.6. Experimental Group: DDN
The experimental group of triathletes of this study received only one session of
DDN for which disposable stainless-steel needles (0.3 × 50 mm, Agupunt, Madrid, Spain)
were used. These needles were introduced into the MTrP after its location within the taut
band [50]. The “fast in, fast out” technique was selected to carry out the DDN treatment [16].
First, the area was cleaned with alcohol, and the therapist wore sterile gloves. The needle
was then held firmly between the thumb and the index finger and was directed with
deepening penetration through the MTrP [51]. The needle moved up and down without
exiting the skin. Finally, the DDN technique was applied for a maximum number of 8–10
insertions or up to the limit of patient tolerance [52].
2.7. Intervention Group: ICT
Ischemic compression is a habitually manual pressure technique. In the present study
this technique was applied to the intervention group of triathletes. In order to carry out this
treatment, pressure was applied with the thumb in the latent MTrP until the pain reached
its maximal tolerable level. This pressure was sustained for 1 min [53].
2.8. Statistical Analysis
Statistical analyses were performed by the software IBM SPSS (version 19.0, IBM Corp.,
Armonk, NY, USA). The Shapiro-Wilk test was performed to assess normality. Group
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differences were examined using, the Student’s t-test for independent variables for the
variables that were adjusted to normal (p > 0.05). For the variables that were not adjusted
to normal, the non-parametric Mann–Whitney U test (p < 0.05) was used. These statistical
analyses were carried out according to the provided sample size calculation and following
prior published secondary analyses of this randomized clinical trial [36,54]. The mean ±
SD, range (minimum – maximum), mean differences and the 95% confidence intervals
(CI) for each outcome measurement were calculated. Furthermore, bar graphs including
95% CI error bars were added in order to illustrate statistically significant differences for
parametric data. All analyses were considered statistically significant at p < 0.05, with a CI
of 95%.
In addition, for outcome measurements, reliability analyses were performed. Calcu-
lation of ICCs, minimum detectable changes (MDCs), standard errors of measurement
(SEM) and lower and upper limits of the 95% CI were obtained. The formula SEM =
SD ×
√
(1-ICC) was used to calculate SEM values and thus measure the error range of
the parameter. The MDC values were calculated to determine the change in magnitude
necessary so that without being influenced by random variations or measurement errors,
confidence changes are provided. SEM and MDC were analysed according to Bland and
Altman. The classification of ICC values was as follows: the value was considered poor
when ICC < 0.40, ICC was fair with an ICC value of 0.40–0.59. ICC was considered good
with value range from 0.60 to 0.74 and ICC value ranging from 0.75–1 was categorized as
excellent [55].
Finally, multivariate regression analyses were carried out in order to predict the EMG
differences after treatments. Linear regression models were carried out by the stepwise
selection method to predict the outcome measurements differences for EMG values at V1
(speed of 1 m/s), V2 (speed of 1.5 m/s) and V3 (speed of 2.5 m/sg) as dependent variables.
Descriptive data, such as sex, height, weight, BMI and foot length, as well as treatment
group (DDN = 0; ICT = 1) were included as independent variables. R2 coefficients were
used to determine the quality of adjustment. Pre-stablished Pin and Pout F-probability
values were set at 0.05 and 0.10, respectively.
3. Results
A total of 46 triathletes were recruited initially to participate in this study. Of all
participants, 12 participants were excluded from the study. Ten were excluded because
they did not present latent MTrPs at the time of the evaluation and two because they
took the medication at the time of study completion. Finally, 34 subjects (20 males and 14
females) agreed to participate in the study. None of the subjects presented any adverse
effects (Figure 1).
3.1. Sociodemographic Characteristic by Treatment Groups.
The demographic data of the sample studied were divided by type of treatment. The
experimental group was treated with DDN, and the intervention group was treated with
ICT. Ages, both in the experimental and intervention groups (35.29 ± 5.39 and 33.76 ±
76 years, respectively) did not present statistically significant differences between them
(p = 0.215). Weight did not present presented statistically significant differences between
experimental and intervention groups 65.17 ± 10.71 and 69.17 ± 10.66 kg, respectively;
p = 0.141. Height did not present statistically significant differences between both ex-
perimental and intervention groups 170.35 ± 12.94 and 174.94 ± 6.96 cm, respectively;
p = 0.103. Body mass index (BMI) did not present statistically significant differences in the
experimental and intervention groups 22.37 ± 1.92 and 22.48 ± 2.35 kg/cm2, respectively;
p = 0.443. Foot length did not show any statistically significant differences between both
groups (p = 0.421) with values in the experimental and intervention groups of 41.55 ± 3.26
and 41.35 ± 2.73 cm, respectively; These results matched the randomization of the sample
when selecting for one treatment or another.
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Figure 1. Flow diagram of patients throughout the course of the study.
3.2. Electromyographic Measurement
According to Tables 1 and 2 and Figure 2, statistically significant differences (p = 0.037)
were shown for a reduction of superficial EMG measurements differences (%) of the
experimental group (DDN) with respect to intervention group (ICT) at a speed of 1 m/s
(V1) immediately after both interventions, although not at speeds of 1.5 m/s (V2) or
2.5 m/s (V3).




(n = 17) p Value
Age (years) 35.29 ± 5.39 (32.73–37.85) 33.76 ± 5.76 (31.02–36.50) 0.215
Weight (kg) 65.17 ± 10.71(60.08–70.27) 69.17 ± 10.66 (64.10–74.24) 0.141
Height (cm) 170.35 ± 12.94 (164.19–176.50) 174.94 ± 6.96 (171.62–178.25) 0.103
BMI (kg/m2) 22.37 ± 1.92 (21.46–23.29) 22.48 ± 2.35 (21.36–23.6) 0.443
Foot length (cm) 41.55 ± 3.26 (40.00–43.11) 41.35 ± 2.73 (40.05–42.65) 0.421
Abbreviations; DDN, deep dry needling; IC, ischemic compression; m2, meter2; cm, centimetres; kg, kilograms;
BMI, body mass index; 95% CI, confidence interval at 95%. Statistical significance for a p < 0.05 value, with a
confidence interval of 95%.
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Table 2. Electromyographic measurement of muscle activity in medial or lateral gastrocnemius.





























































Abbreviations: DDN, deep dry needling; ICT, ischemic compression technique; FPM, mean power frequency (µV), % percentage with
respect to the MVC; EMG, electromyography; V1, speed of 1 m/sg; V2, speed of 1.5 m/sg; V3, speed 2.5 m/sg; * Student’s parametric
t test for independent samples. † Non-parametric Mann–Whitney U test for independent samples. Statistical significance for a p-value
< 0.05 (bold).
Figure 2. Bars graph with 95% confidence intervals (CI) error bars of immediate electromyograp- ic
measurement differences after experimental (DDN) and control (ICT) interventions of muscle activity
in medial or lateral gastrocnemius at a speed of 1 m/s (V1).
3.3. Reliability Analysis
V1 EMG measurements showed excellent reliability with an ICC value of 0.969 (lower
and upper limits of the 95% CI ranging from 0.946 to 0.984), SEM of 2.61% and MDC of
3.19%, both expressed in percentage with respect to the MVC. V2 EMG measurements
also showed excellent reliability with an ICC value of 0.957 (lower and upper limits of the
95% CI ranging from 0.924 to 0.977), SEM of 3.07% and MDC of 3.46%, both expressed in
percentage with respect to the MVC. V3 EMG measurements showed excellent reliability
with an ICC value of 0.952 (lower and upper limits of the 95% CI from 0.914 to 0.975), SEM
of 3.32% and MDC of 3.60%, both expressed in percentage with respect to the MVC.
3.4. Multivariate Prediction Analysis
A statistically significant linear regression prediction model was shown for EMG
outcome measurement differences at V1 (speed of 1 m/s) which was only predicted for
the treatment group (R2 = 0.129; β = 8.054; F [1,32] = 4.734; p = 0.037) showing a reduction
of this difference under DDN treatment. The rest of descriptive data, such as sex, height,
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weight, BMI and foot length, were excluded from this linear regression model according to
the pre-stablished Pin = 0.05 and Pout = 0.10 values. Thus, descriptive data did not influence
nor predict the EMG outcome measurement differences at V1 (speed of 1 m/s). In addition,
linear regression models for EMG outcomes measurements differences at V2 (speed of
1.5 m/s) and V3 (speed of 2.5 m/sg) did not show any valid prediction model.
4. Discussion
DDN is an invasive treatment procedure that requires a thorough understanding of
human anatomy in order to be properly performed [56]. It contains a risk of skin infection
as a continuity solution occurs with this technique. Several cases of possible infection are
described [57] and even Lee et al. described the development of an acute cervical epidural
hematoma as a result of needling therapy in the area [43]. Therefore, a thorough knowledge
of the anatomy is suggested to try to avoid these complications and to be thorough with
hygiene measures. Treatment of latent MTrPs with DDN in gastrocnemius is related to
intramuscular oedema, produced by the needling [50], procedure was associated with
acute pain postneedling [50].
DDN of latent MTrPs leads to a temporary increase in muscle tone in the needling area,
possibly due to intramuscular oedema in this area [58]. Regarding adverse effects of DDN,
in 2014, Cummings et al. reported [59] a case of pneumothorax complications after DDN in
the iliocostalis muscle. A deep spine infection [60] and infected of hip prothesis were also
described too [57]. In addition, a cervical epidural hematoma [61] has been reported after
DDN treatment.
Common adverse effects included bruising, bleeding and pain during and after treat-
ment. Correct technique, proper hygiene and anatomical knowledge are stipulated as
preventive measures to avoid risks [62].
In case of obtaining similar results, how it happens in our study in the post treatment at
1.5 and 2.5 m/s speeds, with both techniques and taking into account the possible adverse
effects resulting from DDN treatment [57,58,61], we would choose the ICT technique as the
better treatment option in patients with latent MTrPs in gastrocnemius considering their
EMG activity.
In the triceps surae the existence of latent MTrPs is associated with future muscular
dysfunction [63].
A 2013 study [64], found a high percentage of latent MTrPs in the asymptomatic
population and located a high prevalence of this point in the gastrocnemius muscle [64]
In keeping with the integrated hypothesis of a trigger point proposed by Simons,
the zone around an MTrP is in an ischemic state with a shortage of glucose and oxy-
gen [65]. Therefore, treatment with compression of MTrPs helps to improve sarcomere
contractions [66].
Takamoto et al. demonstrated that compression applied to the MTrPs would affect
to autonomic nervous activity [67]. They published a study in 2009 [67] in which MTrP
compression elevated the activity of the parasympathetic nervous system and showed that
the physiological mechanisms of pain relief could be induced by the pressure application
over MTrPs. That increase entailed an increase in peripheral blood [68], one of the more
important factors involved in relieving muscle fatigue [67]. The increased blood flow,
provides a concurrent increased in the glucose availability to the muscle [69].
The insertion of a needle at the endplate region reduced the quantity of acetylcholine
(ACh) by increasing discharges, leading to a lesser SEA. Hsieh et al. they found an increase
in a number of hypoxic-responsive proteins after DDN stimulation that can promote
angiogenesis, vasodilation, and altered glucose metabolism in MTrP location [69].
In this study, the effects of DDN at the precise site of latent MTrPs, as compared with
those of ICT in the same location shows measure differences in the superficial EMG results,
immediately after treatment, at 1 m/s speed.
At a speed of 1 m/s, triathletes with latent MTPs, treated with DDN, immediately
improve their muscular activity compared to those treated with ICT; in such a way that
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those triathletes who begin their recovery at low training speeds after injuries, they should
receive as treatment, DDN.
Based on our results, from 1.5 m/s of training speed, the activity data of muscle in
triceps surae of triathletes with latent MTPs are similar, so treatment with ICT is recom-
mended, when seeking to demonstrate less adverse effects.
A study on intramuscular EMG in latent MTrPs, in this case the trapezius, associated
their existence with accelerated muscle fatigue, although patients did not have painful
symptoms [65]. These results did not match what we found in our study, in which it
was shown that despite deactivating the latent MTrP from both treatment techniques the
results of EMG measurements were very similar to those before the treatment, perhaps
conditioned by the immediately measurement.
With intramuscular EMG it is evident that a reduction in the fatigue progression
measurement appears earlier in latent MTrPs muscle fibres than in muscle fibres without
latent MTrP during a sustained isometric contraction [26]. These results suggest that latent
MTrPs are associated with accelerated muscle fatigue.
The muscles fibres of latent MTrPs showed increased motor activity during contrac-
tion [10] when the measured was made with surface EMG. Measured with intramuscular
EMG the activity in latent MTrPs was much higher than in areas where there is not latent
MTrPs both at rest and in isometric contraction [24]. On the other hand when the mea-
surement is made with surface EMG, there are no notable differences between the results
obtained at rest and during the contraction [24].
Hong et al. conduced a study in 2014 in which an increase in surface EMG activity in
latent MTrPs in the upper trapezius muscle when the muscle was submitted to low loads
(25% of MVC) and short times (less than 10 s) of isometric contraction was not observed.
On the other hand when the muscle was subject to low loads (25% of MVC) and somewhat
longer times (7 min) of isometric and fatigue contractions an increase in surface EMG
activity in latent MTrPs was induced [24]. These results may not contradict with those in
our study because the performed contraction by triathletes was concentric in the Hong
study. In 2019, Baraja-Vegas et al. published a study in which they used DN over latent
MTrPs of medial gastrocnemius muscle and observed that the RMS peak amplitude of
each subsequent LTR decreased when compared with the initial RMS peak amplitude of
previous LTRs [70].
Another study in computer workers related to upper trapezius muscle demonstrated
a small decrease in superficial EMG activity after the application of ICT [52] or DN [71].
In previous studies by our research group, we observed that both interventions DDN
and ICT showed similarly efficacy in treatment of latent MTrPs in the gastrocnemius of
triathletes in terms of dorsiflexion of tibiofibular-talar joint in addiction to changes in static
and dynamic plantar pressures [36]. In addition, when our research group measured the
pressure pain threshold (PPT) and thermography in latent MTrPs of triathletes treated with
both techniques, we observed that local mechanosensitivity had immediately increased
after treatment with DDN while this increase did not occur when triathletes were treated
with ICT [72].
ICT has demonstrated moderately strong evidence for immediate pain relief in MTrPs,
but this evidence is limited in terms of long-term pain relief. A recent review of the literature
demonstrated moderately strong evidence supporting the use of ischemic pressure for
immediate pain relief at the TrPs, but only limited evidence for long-term pain relief [73].
The great pressure stimulus caused by the needle on the MTrP sends strong neural
impulses to the posterior horn, breaking the pain-spasm-pain circle of the MTrP as described
by the gate control theory [74].
Hsieh et al. [75] demonstrated that when LTRs were elicited by DDN to a MTrP region
suppression of spontaneous electrical activity (SEA) occurred.
According to the various theories, deactivation of trigger points may be attributed
to mechanical [32], and biochemical [76] changes around needle insertion. One study
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demonstrated a decrease in motor end-plate hyperactivity in MTrP, in patients treated with
DDN [77].
Sympathetic system regulation can be affected by the effects of needle insertion, and
DDN might cause reduction of sympathetic response after treatment with this method [61].
Several authors have theorized about the possibility that rapid movement of the
needle into a MTrP might stimulate afferent fibres and could block the pain information
generated in the MTrP´s nociceptors though a ”gate control” mechanism [78].
In 2019, Barajas et al, conducted a study in which only superficial EMG changes,
after the completion of DDN in latent MTrP were described. The decrease in local twitch
response amplitudes (brief and sudden contractions of the MTrP taut band) peak after
DDN with respect to before DDN treatment in the latent MTrPs [70].
In addition, treatment of latent MTrPs with DDN is related to intramuscular oedema,
an improvement of muscle contraction reaction, and increase in muscle stiffness [57].
5. Limitations
As a main limitation, this study reflected only the EMG measurement results imme-
diately after an intervention, and an intervention group with placebo treatment was not
used.
Another limitation was pain measurements of were not obtained in this study because
the aim in this study was measure EMG activity in latent MTrPs.
The fact that a single treatment session was carried out, and in the case of ICT, of only
60 s., could determine that the treatment was scarce in order to see results.
6. Conclusions
DDN administration requires experience and excellent anatomical knowledge. Ac-
cording to our findings immediately after treatment of latent MTrPs when the muscle was
subdued due to a concentric contraction, DDN could be advisable for triathletes who train
at a speed lower than 1 m/s, those who begin their recovery at low training speeds after
injuries, they should receive as treatment, DDN, while ICT could be a more advisable
technique than DDN for training or competition at speeds greater than 1.5 m/s. Further
studies with longer follow-up periods and placebo interventions are suggested.
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